Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
USV | Ann: Smartshares Limited - Change of Address | 07/10/24 | 0 | 17 | |||
|
|||||||
USV | Ann: USV NTA 04-10-2024 $5.49645 | 07/10/24 | 0 | 19 | |||
|
|||||||
USV | Ann: USV NTA 03-10-2024 $5.48114 | 04/10/24 | 0 | 44 | |||
|
|||||||
USV | Ann: USV NTA 02-10-2024 $5.45906 | 03/10/24 | 0 | 34 | |||
|
|||||||
USV | Ann: USV NTA 01-10-2024 $5.41232 | 02/10/24 | 0 | 39 | |||
|
|||||||
USV | Ann: USV NTA 30-09-2024 $5.39108 | 01/10/24 | 0 | 38 | |||
|
|||||||
USV | Ann: USV NTA 27-09-2024 $5.41606 | 30/09/24 | 0 | 39 | |||
|
|||||||
USV | Ann: USV NTA 26-09-2024 $5.42759 | 27/09/24 | 0 | 59 | |||
|
See All Discussions